FT Vest International Equity Moderate Buffer ETF - December (BATS: YDEC)

FT Vest International Equity Moderate Buffer ETF - December (BATS:YDEC), Trade Ideas

FT Vest International Equity Moderate Buffer ETF - December

A federal judge in New York has rejected former President Donald Trump&#8217;s appeal for a new trial in a defamation lawsuit filed by writer E. Jean Carroll. The judge upheld the $83.3 million damage award to Carroll.
What Happened: Judge Lewis Kaplan dismissed Trump&#8217;s arguments for a new trial on Thursday. Kaplan stated that the compensatory damages awarded to Carroll were not solely for emotional distress and were not excessive, <a href="https://abcnews.go.com/Politics/federal-judge-rejects-donald-trumps-bid-new-jean/story?id=109634929">reported</a> ABC News.
He further noted that Trump&#8217;s &#8220;malicious and unceasing attacks&#8221; on Carroll, which reached over 100 million people, included public threats and personal attacks, putting Carroll&#8217;s health and safety at risk.
See Also: <a href="https://www.benzinga.com/news/24/04/38423358/bill-ackman-says-not-voting-for-biden-slams-president-for-inaction-on-american-hostage-issue-too-foc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bill Ackman Says &#8216;Not Voting For Biden,&#8217; Slams President For Inaction On American Hostage Issue: &#8216;Too Focused On Other Talking Points…To Get Re-elected&#8217;</a>
Roberta Kaplan, Carroll&#8217;s attorney, expressed satisfaction with the court&#8217;s decision, stating it was &#8220;entirely reasonable&#8221; for the jury to award Carroll $83 million in damages given Trump&#8217;s continued defamation during the trial.
Earlier in February, following a five-day trial, Trump was ordered to pay Carroll, a former Elle magazine columnist, $83.3 million for defaming her in 2019 when he denied her allegations of sexual abuse. The award included $17.3 million in compensatory damages and $65 million in punitive damages.
In May 2023, in a separate trial, Trump was found liable for sexually abusing Carroll in a Manhattan department store in the 1990s and defaming her in a 2022 social media post. However, the jury did not find Trump guilty of rape as claimed by Carroll.
Why It Matters: This lawsuit has been a significant legal battle for Trump. In January, a federal jury in Manhattan <a href="https://www.benzinga.com/news/24/01/36812707/donald-trump-ordered-to-pay-83m-to-e-jean-carroll-in-defamation-lawsuit">ordered Trump to pay</a> Carroll $83.3 million in a defamation lawsuit.
Following the verdict, Trump <a href="https://www.benzinga.com/news/24/03/37572257/e-jean-carroll-case-trump-posts-91-6m-bond-as-ex-president-appeals-against-defamation-verdict">posted a $91.6 million bond</a> to appeal the defamation verdict in March 2024. The bond, provided by Federal Insurance Co, a part of the insurer Chubb, would cover Carroll's $83.3 million judgment if Trump loses his appeal and refuses to pay.
Read Next: <a href="https://www.benzinga.com/news/24/04/38394472/trump-vp-pool-including-a-mystery-candidate-put-on-notice-by-anti-abortion-group-gop-ticket-poses-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">TTrump VP Pool, Including A Mystery Candidate, Put On Notice By Anti-Abortion Group: &#8216;GOP Ticket Poses A Significant Threat&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

News

Politics

General

Trump's Request For New Trial In Rape Defamation Trial Rejected, Judge Says Ex-President's Attacks On E. Jean Carroll 'Malicious And Unceasing'

The White House has turned down Republican Speaker Mike Johnson&#8217;s (R-La.) call to deploy the National Guard on college campuses that are witnessing large-scale protests over the Israel-Hamas conflict.
What Happened: House Speaker Johnson, on Thursday, urged President Joe Biden to mobilize the National Guard to suppress the widespread protests on college campuses related to the Israel-Hamas war, as <a href="https://thehill.com/homenews/administration/4622494-white-house-biden-republican-national-guard-college-israel-palestine-protests/">reported</a> by The Hill. Johnson had visited Columbia University on Wednesday, where the first major pro-Palestine protest took place and has since proliferated to several colleges across the country.
In response, White House spokesperson Karine Jean-Pierre clarified on Thursday that the power to deploy the National Guard lies with state governors, not the president. Jean-Pierre also reminded that President Biden has previously condemned the protests as antisemitic.
&#8220;That is something for the governors to decide," she told reporters, according to the report.
Despite this, Johnson intensified his rhetoric on Wednesday, describing the protests as &#8220;dangerous&#8221; and suggesting that it might be the &#8220;appropriate time for the National Guard&#8221; if the &#8220;threats and intimidation&#8221; are not swiftly curbed.
The protests, involving students and faculty, are urging the Biden administration to back a permanent cease-fire in the Israel-Hamas conflict, halt military aid to Israel, and are advocating for their universities to divest from Israeli interests.
See Also: <a href="https://www.benzinga.com/news/24/04/38394472/trump-vp-pool-including-a-mystery-candidate-put-on-notice-by-anti-abortion-group-gop-ticket-poses-a?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump VP Pool, Including A Mystery Candidate, Put On Notice By Anti-Abortion Group: &#8216;GOP Ticket Poses A Significant Threat&#8217;</a>
Why It Matters: The protests have been gaining momentum since April 2024. Students began demanding their universities to <a href="https://www.benzinga.com/news/24/04/38446778/students-demand-universities-sell-off-israel-related-stocks-hundreds-arrested-in-nationwide-protests">divest from Israeli-related stocks</a>. The protests, which started at Columbia University, have led to hundreds of arrests nationwide. 
Political figures such as former Vice-President Mike Pence and Sen. Tim Scott (R- S.C.) have <a href="https://www.benzinga.com/news/24/04/38358514/mike-pence-tim-scott-slam-pro-palestinian-protests-in-columbia-university-no-place-for-anti-semitism">criticized the protests</a>, with Pence stating, "There is no place for Antisemitism in any form in any place in the United States of America." 
Read Next: <a href="https://www.benzinga.com/news/24/04/38422645/trumps-niece-says-ex-president-could-see-potential-imprisonment-as-opportunity-donald-is-facing-real?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Niece Says Ex-President Could See Potential Imprisonment As Opportunity: &#8216;Donald Is Facing Real-Time Consequences For His Transgressions&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

White House Declines Mike Johnson's Request For National Guard Deployment Amid College Protests Over Israel-Hamas Conflict: 'Something For The Governors To Decide'

The U.S. Supreme Court&#8217;s conservative justices are deliberating over former President Donald Trump&#8217;s claim for immunity from prosecution for actions taken during his presidency.
What Happened: The Supreme Court justices are examining Trump&#8217;s assertion that U.S. presidents should be granted &#8220;absolute immunity&#8221; for official acts. Trump, who is aiming to return to the White House, is seeking to avoid prosecution for actions he undertook while in office that resulted in his indictment by Special Counsel Jack Smith, reported Reuters on Thursday.
Although the justices seem unlikely to fully support Trump&#8217;s claim of absolute immunity, they expressed concerns about presidents not having any degree of immunity, particularly for less serious acts. The exact scope of such a ruling, however, is yet to be determined.
Trump appealed after lower courts rejected his request for immunity from four election-related criminal charges. The Supreme Court&#8217;s decision could potentially limit the charges against Trump, but it seems that parts of the indictment will persist.
Conservative Justice Samuel Alito expressed apprehensions about the possibility of retaliatory prosecution by future administrations, while Chief Justice John Roberts voiced concerns about potential misuse of prosecutions of presidents in the absence of immunity.
Alito asked a lawyer representing Smith, &#8220;Will that not lead us into a cycle that destabilizes the functioning of our country as a democracy?&#8221;
&#8220;We can look around the world and find countries where we have seen this process where the loser gets thrown in jail,&#8221; said Alito, according to the report.
See Also: <a href="https://www.benzinga.com/news/24/04/38395938/kim-jong-uns-sister-pledges-to-build-north-koreas-overwhelming-military-power-amid-rising-regional-t?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Kim Jong Un&#8217;s Sister Pledges To Build North Korea&#8217;s &#8216;Overwhelming&#8217; Military Power Amid Rising Regional Tensions</a>
Why It Matters: This case marks the <a href="https://www.benzinga.com/news/24/04/38420493/trumps-presidential-immunity-claim-under-supreme-court-review-its-so-fundamental-to-the-presidency">first time</a> the Supreme Court is reviewing an appeal from one of Trump's criminal indictments. Trump's defense, which claims immunity from prosecution even post-presidency, has been rejected by two lower courts previously.
Despite the potential dismissal of Trump&#8217;s broad immunity argument by the Supreme Court, the case could <a href="https://www.benzinga.com/news/24/04/38348880/donald-trump-could-still-win-even-if-he-loses-in-supreme-court-over-presidential-immunity-claim">still be redirected</a> to U.S. District Court Judge Tanya Chutkan for further examination, offering a strategic victory for Trump.
Trump&#8217;s request to <a href="https://www.benzinga.com/news/24/04/38262159/trumps-request-to-attend-supreme-court-hearing-barrons-high-school-graduation-denied-by-hush-money-t">attend the Supreme Court arguments</a> was denied due to his ongoing trial in New York.
The court&#8217;s decision, expected by the end of June, could further delay Trump&#8217;s trial and potentially impact the upcoming presidential election.
Photo Courtesy: Shutterstock.com
Read Next: <a href="https://www.benzinga.com/news/24/04/38394597/elon-musk-reacts-to-marjorie-taylor-greenes-ally-revelation-of-fine-threat-by-house-authorities-mike?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Reacts To Marjorie Taylor Greene&#8217;s Ally Revelation Of Fine Threat By House Authorities: Mike Johnson Removing Traces Of &#8216;Betrayal of America&#8217;</a>
<div style="font-family: 'Lato', sans-serif">
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by 
 Benzinga Neuro, Edited by 
 
 <a href="None" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none"> 
 Shivdeep Dhaliwal</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the 
 extensive Benzinga Ecosystem, including native data, APIs, and more to 
 create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>

Supreme Court Justices Weigh 'Absolute Immunity' For Trump, Lean Toward Some Protection: 'We Have Seen This Process Where The Loser Gets Thrown In Jail'

ISUN

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

ATXI

ZVSA

Aurora Cannabis Inc.&nbsp;captured investor attention with a dramatic 38% increase in options trading and a significant 18.2% surge in stock price in a single trading day.
These movements underscore a robust financial period for the company, which reported quarterly revenues of $53.34 million, surpassing expectations by nearly 16%.
<h2>Stock Performance Overview</h2>
On a notable Tuesday, Aurora Cannabis Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acb#NASDAQ">ACB</a>) witnessed a surge in options trading activity. The cannabis company observed investors purchasing 24,073 call options, a stark 38% increase <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38149371/nasdaq-listed-marijuana-stocks-tilray-canopy-aurora-rally-whats-behind-the-surge">over the typical volume </a>of 17,462 options.&nbsp;
On the same trading day, Aurora saw its <a href="https://www.marketbeat.com/instant-alerts/nasdaq-acb-options-data-report-2024-04-23/">stock price surge</a> by 18.2%, climbing $1.14 to close at $7.42. Trading volume for the day dramatically increased to 9,331,051 shares, nearly doubling the average volume of 4,809,986 shares.
The company demonstrated a low debt-to-equity ratio of 0.14, and currently, boasts a market capitalization of $404.69 million, despite a negative price-to-earnings ratio of -2.56.&nbsp;
This means that despite its negative earnings metrics, Aurora maintains a strong liquidity position and a stable financial structure, which could reassure investors about its ability to manage short-term <a href="https://www.benzinga.com/markets/cannabis/24/03/37422276/aurora-cannabis-bounces-back-debt-paid-growth-ahead">obligations and debts</a>.
The company&#39;s significant market capitalization also reflects a level of investor confidence in its potential for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37353256/all-you-need-to-know-about-the-german-marijuana-market-changes-size-and-leading-pla">long-term growth</a> and recovery.
<h3>Recent Stock Dynamics</h3>
Later in the week, ACB shares experienced a dip, opening at $7.20 on Thursday, reflecting the stock&#39;s ongoing volatility.
Despite reaching a 52-week high of $11.50 and a low of $2.84, Aurora has maintained relatively stable long-term price trends, with a 50-day moving average of $4.51 and a 200-day moving average of $4.56.
This pattern underscores the stock&#39;s fluctuating yet consistent performance within the market.
<h3>Financial Health And Earnings Insight</h3>
Aurora Cannabis disclosed its earnings on February 8th, reporting a quarterly loss of $0.20 per share, which fell short of the consensus estimates predicting a $0.10 loss per share.
However, the company&#39;s revenue reached $53.34 million, exceeding the expected $45.94 million. Despite these revenue gains, Aurora Cannabis continues to wrestle with a substantial negative net margin of 48.82% and a negative return on equity of 23.27%.
The company&rsquo;s financial structure remains solid, underscored by <a href="http://www.marketbeat.com/instant-alerts/nasdaq-acb-options-data-report-2024-04-23/">indicators of&nbsp;strong liquidity</a>. The combination of underperforming profit metrics and surpassing revenue forecasts suggests that while Aurora is effective at generating sales, it faces challenges in translating these revenues into net profits.
The substantial negative net margin and return on equity highlight ongoing operational or financial inefficiencies. However, the solid liquidity ratios reassure stakeholders of the company&#39;s ability to sustain its<a href="https://www.benzinga.com/markets/cannabis/24/03/37848787/aurora-cannabis-earns-coveted-gmp-certification-for-australian-market-heres-what-it-means"> operations</a> and potentially invest in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37896976/cannabis-stocks-set-to-dominate-germanys-new-market-a-surge-in-demand-meets-establi">strategic initiatives</a> to improve profitability.
<h3>Institutional Investor Engagement</h3>
In recent months, Aurora Cannabis has seen significant <a href="https://www.benzinga.com/markets/cannabis/24/03/37755041/cannabis-stocks-jump-on-news-that-dea-may-soon-undertake-marijuana-reform">shifts</a> in institutional investment. MMCAP International Inc. SPC established a new position worth approximately $4.659 million.
Cambria Investment Management L.P. notably increased its holdings by 115.5%, while Mirae Asset Global Investments Co. Ltd. expanded its stake by 6.3%.
Similarly, Vontobel Holding Ltd. boosted its investment by 67.5%, holding 125,304 shares valued at $73,000.
These movements highlight <a href="https://www.benzinga.com/markets/cannabis/24/03/37568032/aurora-cannabis-exec-says-company-well-positioned-in-germany-will-push-for-expansion-of-medical-">growing confidence</a> among major financial players, with institutional investors now owning 47.63% of the company&rsquo;s stock, as <a href="https://www.etfdailynews.com/2024/04/25/investors-purchase-large-volume-of-aurora-cannabis-call-options-nasdaqacb/">reported</a> by ETF Daily News.
Photo: AI-Generated Image.&nbsp;

Analyst Color

Cannabis

Options

Retail Sales

Small Cap

Markets

Analyst Ratings

Trading Ideas

Investors Shuffle Stock Positions In Aurora Cannabis: Beyond Earnings, Liquidity Looks Appealing

Continuing her commitment to criminal justice reform,&nbsp;businesswoman and celeb&nbsp;Kim Kardashian met with <a href="https://www.benzinga.com/markets/cannabis/24/03/37760731/vp-kamala-harris-urges-dea-to-reschedule-cannabis-as-quickly-as-possible-calls-prohibition-absur">Vice President Kamala Harris </a>to discuss new strategies for addressing <a href="https://www.benzinga.com/cannabis">marijuana policies</a>.
The meeting, which took place at the White House, highlighted President Joe Biden&#39;s <a href="https://www.benzinga.com/markets/cannabis/24/04/38412810/president-biden-pardons-commutes-16-non-violent-drug-offenders-cannabis-prisoners-excluded">recent use of clemency powers</a>, particularly for non-violent&nbsp;offenses.
<h3>Presidential Clemency</h3>
Recently, Biden pardoned 11 individuals and commuted the sentences of five others, all convicted for non-violent drug-related activities, underlining a shift towards more lenient sentences under current laws. This move aligns with his broader efforts to rectify past judicial discrepancies.
The <a href="https://apnews.com/article/kamala-harris-kardashian-criminal-justice-reform-biden-d34ae7fb30b1fe78326dafad230611d0">event</a> was marked by heartfelt stories from those pardoned, sharing tales of newfound opportunities and personal growth post-incarceration. Kardashian, reflecting on the gathering, emphasized the importance of amplifying such stories to inspire others in similar situations.
<h3>Historical Advocacy</h3>
Kardashian has been a vocal advocate for criminal justice reform, notably influencing policy during the Trump administration alongside Jared Kushner.
Her efforts have led to significant legal changes and individual pardons, including the high-profile case of Alice Marie Johnson in 2018.
<h3>Loan Restrictions</h3>
VP Harris announced a new rule from the Small Business Administration, aimed at easing loan restrictions for individuals with criminal records. This policy intends to facilitate reintegration and <a href="https://www.npr.org/2024/04/25/1247183807/kim-kardashian-white-house-criminal-justice-reform">provide second chances</a>.
&quot;Reducing and eliminating that restriction is going to mean a lot in terms of second chances and the opportunity for people to excel,&quot; Harris <a href="https://www.npr.org/2024/04/25/1247183807/kim-kardashian-white-house-criminal-justice-reform">said</a>.
The Biden administration has consistently worked towards reducing penalties for drug offenses, notably expanding a sweeping pardon for those convicted of simple <a href="https://www.benzinga.com/markets/cannabis/24/04/37988501/59-of-americans-support-right-to-grow-legal-cannabis-at-home-new-survey-finds">marijuana</a> possession&mdash;a move that resonates strongly with many voters, particularly young and minority groups.
This collaboration between Kardashian and Harris not only underscores the ongoing reform efforts but also showcases the influential role celebrities can play in shaping public policy and social justice.
Photo via Wikimedia Commons

Entertainment

Government

Regulations

Legal

Kim Kardashian And VP Harris Discuss Cannabis Justice Reform And 'Second Chances' At The White House

Citigroup analyst Atif Malik maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Neutral and lowers the price target from $137 to $120.

Price Target

SLAB

Citigroup Maintains Neutral on Silicon Laboratories, Lowers Price Target to $120

In a compelling showcase of how sports figures leverage their platforms beyond the field, former NFL athletes <a href="https://www.benzinga.com/general/sports/24/04/38358885/joique-bell-to-discuss-journey-from-rookie-to-prominent-nfl-running-back-at-benzinga-draft-event">Joique Bell</a> and<a href="https://www.benzinga.com/markets/cannabis/24/03/37797148/former-nfl-legends-bring-top-cannabis-strains-to-boston-with-launch-of-primitiv"> Rob Sims</a> shared their philanthropic journeys today (April 25) during the <a href="https://www.youtube.com/watch?v=93htkUYdGNc">Benzinga Sports Business Titans Draft</a> event in Detroit. 
The panel, adjacent to the NFL Draft at Campus Martius, highlighted the transformative impact athletes can have in their communities post-retirement.
<h1 class="wp-block-heading">Athletes Turned Philanthropists</h1>
Moderated by Rachel Decker, president of Detroit Philanthropy, the conversation delved into the personal motivations behind the athletes&#8217; commitments to giving back. 
Bell, a Michigan native and former Detroit Lion, emphasized the influence of his upbringing on his charitable efforts. 
&#8220;Growing up, being involved in community service was ingrained in me by my parents,&#8221; Bell said. He discussed his focus on literacy and education through his foundation, which aims to improve reading levels among students within a short period significantly.
Sims, who transitioned from the gridiron to various business and charitable endeavors, highlighted his strategic approach to philanthropy. 
&#8220;It&#8217;s about making an impact with the resources we have, ensuring our efforts genuinely help those in need,&#8221; Sims stated. His involvement with local organizations such as Detroit PAL and the Children&#8217;s Center demonstrates his commitment to youth and community health.
<h1 class="wp-block-heading">Impact And Influence&nbsp;</h1>
The discussion also covered the athletes&#8217; strategies for selecting and managing philanthropic engagements. 
Both Bell and Sims stressed the importance of aligning with causes that reflect their values and where they can make a meaningful difference. Bell shared his rigorous approach to vetting organizations before partnering with them, ensuring alignment with his goals to support community development.
<h1 class="wp-block-heading">Advice For The Next Generation&nbsp;</h1>
As the event drew the attention of young athletes and aspiring philanthropists, Bell and Sims offered advice on starting and running charitable foundations. 
&#8220;Understand the work that goes into managing a foundation; it&#8217;s akin to running a business,&#8221; Sims advised. Bell echoed this sentiment, emphasizing the importance of commitment and genuine passion for the cause.
<h1 class="wp-block-heading">Legacy Beyond The Field&nbsp;</h1>
Reflecting on their legacies, both athletes expressed a desire to be remembered for their contributions off the field as much as their achievements on it. 
&#8220;It&#8217;s not just about the sports; it&#8217;s about using our platform to make a lasting impact,&#8221; said Bell.
Photo by Dustin Blitchok.

Sports

Events

Game Changers: Ex-NFL Players Talk Philanthropy For Today And Next-Gen At Benzinga Titans Draft Event

Citigroup analyst Ronald Josey maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Neutral and lowers the price target from $320 to $280.

Citigroup Maintains Neutral on Lithia Motors, Lowers Price Target to $280

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $94 to $91.

BMRN

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91

Citigroup analyst Michelle Fang maintains New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) with a Buy and raises the price target from $66 to $127.

New Oriental Education & Technology Group

Citigroup Maintains Buy on New Oriental Education, Raises Price Target to $127

Citigroup analyst Andrew Kaplowitz maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Buy and lowers the price target from $101 to $98.

Citigroup Maintains Buy on Fortive, Lowers Price Target to $98

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Guidance

MSFT

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Citigroup analyst Anthony Pettinari maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Neutral and lowers the price target from $183 to $181.

Citigroup Maintains Neutral on Packaging Corp of America, Lowers Price Target to $181

Citigroup analyst Christopher Allen maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and raises the price target from $22.5 to $24.5.

VIRT

Citigroup Maintains Buy on Virtu Finl, Raises Price Target to $24.5

Citigroup analyst Thomas Palmer maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and raises the price target from $117 to $122.

Citigroup Maintains Buy on Bunge Global, Raises Price Target to $122

Citigroup analyst Fatima Boolani maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and lowers the price target from $20 to $15.

FSLY

Citigroup Maintains Neutral on Fastly, Lowers Price Target to $15

Citigroup analyst Fatima Boolani maintains Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) with a Neutral and lowers the price target from $140 to $117.